banner: 2016 best of lung cancer summmit

Conference Home

Scientific Agenda

Accommodations & Travel

Sponsorship

The Best of Lung Cancer Summit

OncologyEducation is proud to host The Best of Lung Cancer Summit in Toronto, Ontario. This full-day event takes the most significant lung cancer data from the 2017 ASCO and ESMO conferences, and puts it into context for oncology professionals. Speakers will review the latest research with in-depth analysis and discussion to improve the current standard of lung cancer care. This event will be Chaired by Dr. Ronald Burkes. 


Meeting Objectives

After taking part in the program, participants will be able to:
1. Describe the current and future availability and application of immunotherapy in the treatment of lung cancer.
2. Understand the latest strategies for managing lung cancer with radiation therapy and/or surgery.
3. Discuss approaches for maximizing outcomes on the standard of care in the management of lung cancer using biomarker testing, targeted therapies and other new targets. 


FEES

Early Bird Price
(Ending September 23, 2017):
Nurses/Pharmacists/Residents/Students/Allied Healthcare Providers: $45 CAD
Physicians: $89 CAD

Regular Price
(After September 23, 2017):
Nurses/Pharmacists/Residents/Students/Allied Healthcare Providers: $65 CAD
Physicians: $129 CAD


ABOUT THE CHAIRS

 

Dr. Ronald L. Burkes, MD, FRCPC

Dr. Ron Burkes is Professor of Medicine at The University of Toronto and staff medical oncologist at Mount Sinai Hospital/Princess Margaret Cancer Centre/University Health Network in Toronto. He was the program director for the medical oncology training program at the University of Toronto from 1996 to 2005 and director of the Clinical Teaching Unit at PMH from 1999 to 2005.  He has won numerous teaching awards including departmental and university wide awards on 17 occasions, the Anderson Award in Program Development and the Hasselback Teaching Award at PMCC. He has presented at many local, provincial, national and international meetings.

His research interests include lung and GI malignancies with a primary interest in colorectal and gastric cancers. He has numerous publications including 105 peer reviewed, 138 non-peer reviewed and 2 book chapters. 

Dr. Barbara Melosky, MD, FRCPC

Dr. Melosky is a Associate Professor of Medicine at the University of British Columbia and a Medical Oncologist at the British Columbia Cancer Agency. She graduated from medical school at the University of Manitoba and did a residency in internal medicine and a oncology fellowship at the University of British Columbia.

She is currently a medical oncologist at the BC Cancer Agency with clinical interests in lung and gastrointestinal malignancies.

 


 Please contact Lucas Severin, Event Coordinator, at lucas@oncologyeducation.com with any inquiries.

 

 

 

Member Comments. (0)

Oncology Clinical News

Celgene Settles Whistle-Blower Fraud Suit for $280 Million

(Bloomberg) July 25, 2017 - Celgene Corp. agreed to pay $280 million to resolve a whistle-blower’s claims the drugmaker used illegal marketing tactics to turn its Thalomid and Revlimid cancer drugs into blockbuster sellers, the U.S. said.
Read full article.

Eisai Submits Simultaneous Applications In The United States And Europe For Lenvatinib In Hepatocellular Carcinoma

(Eisai) July 25, 2017 - Eisai Co., Ltd. announced that it has submitted applications to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its in-house discovered and developed anticancer agent lenvatinib mesylate (lenvatinib) for the treatment of hepatocellular carcinoma (HCC).
Read full article.

Roche Gains CE Label Expansion For Companion Diagnostic To Identify ALK-positive Non-small Cell Lung Cancer Patients

(Yahoo! Finance) July 25, 2017 - Roche today announced that it has obtained a CE mark for the VENTANA anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC) patients eligible for treatment with the Novartis drug ZYKADIA (ceritinib).
Read full article.

Powered by OBR Oncology